These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21878748)

  • 1. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
    Inoue H; Hwang SH; Wecksler AT; Hammock BD; Weiss RH
    Cancer Biol Ther; 2011 Nov; 12(9):827-36. PubMed ID: 21878748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
    Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
    Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
    Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Liu Q; Mier JW; Panka DJ
    Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
    Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Masubuchi D; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
    Int J Oncol; 2010 Jun; 36(6):1521-31. PubMed ID: 20428777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
    Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
    Matsuda Y; Fukumoto M
    Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
    Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.